AI

Alumis Inc. Common Stock

ALMS·NASDAQ

$20.57

+2.4%
HealthcareBiotechnology

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$2.54B
EPS-2.8600
P/E Ratio-7.19
Earnings Date08/12/2026

alms

Investments in Property, Plant, and Equipment

Last Annual Value

-653.00K

3-Year CAGR

35%

5-Year CAGR

23%

10-Year CAGR

12%

AI

Alumis Inc. Common Stock Competitors Analysis of Investments in Property, Plant, and Equipment

ALMS · NASDAQ
CompanyInvestments in Property, Plant, and Equipment
CAGR 3Y
CAGR 5Y
CAGR 10Y
-653.00K
N/AN/AN/A 
-333.00K
N/AN/AN/A
0.00
N/AN/AN/A
-314.00K
N/AN/AN/A
0.00
N/AN/AN/A
-122.00K
N/AN/AN/A
OCGN logo
Ocugen, Inc.
NASDAQ:OCGN
-185.00K
N/AN/AN/A
-522.00K
N/AN/AN/A
-65.00K
N/AN/AN/A
AI

Alumis Inc. Common Stock Fair Value Envelope

ALMS · NASDAQ

Our analysis suggests that ALMS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.57, this represents a potential HIDDEN relative to our calculated worth for Alumis Inc. Common Stock.

Intrinsic Value
Current Price: $20.57